Compare Stocks: BBOT, NVAX, BCAX, and AAPG

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AAPG Ascentage Pharma Group International	$15.49 -3.2%	$18.02	$15.40 ▼ $40.47	$1.45B	0.08	6,823 shs	2,548 shs
BBOT BridgeBio Oncology Therapeutics	$4.77 -2.3%	$8.52	$4.72 ▼ $14.87	$383.37M	0.38	382,859 shs	411,480 shs
BCAX Bicara Therapeutics	$22.30 -1.6%	$25.61	$10.30 ▼ $30.99	$1.48B	-0.82	594,229 shs	373,951 shs
NVAX Novavax	$9.24 +0.1%	$8.62	$6.20 ▼ $11.97	$1.53B	2.45	4.72 million shs	1.28 million shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AAPG Ascentage Pharma Group International	-2.96%	-8.69%	-15.49%	-6.82%	-58.78%
BBOT BridgeBio Oncology Therapeutics	-3.37%	-44.92%	-46.14%	-36.46%	+487,999,900.00%
BCAX Bicara Therapeutics	-2.28%	-4.39%	-6.63%	-1.09%	+99.21%
NVAX Novavax	-3.75%	-9.42%	+14.66%	-2.84%	+14.23%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AAPG Ascentage Pharma Group International	$15.49 -3.2%	$18.02	$15.40 ▼ $40.47	$1.45B	0.08	6,823 shs	2,548 shs
BBOT BridgeBio Oncology Therapeutics	$4.77 -2.3%	$8.52	$4.72 ▼ $14.87	$383.37M	0.38	382,859 shs	411,480 shs
BCAX Bicara Therapeutics	$22.30 -1.6%	$25.61	$10.30 ▼ $30.99	$1.48B	-0.82	594,229 shs	373,951 shs
NVAX Novavax	$9.24 +0.1%	$8.62	$6.20 ▼ $11.97	$1.53B	2.45	4.72 million shs	1.28 million shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AAPG Ascentage Pharma Group International	-2.96%	-8.69%	-15.49%	-6.82%	-58.78%
BBOT BridgeBio Oncology Therapeutics	-3.37%	-44.92%	-46.14%	-36.46%	+487,999,900.00%
BCAX Bicara Therapeutics	-2.28%	-4.39%	-6.63%	-1.09%	+99.21%
NVAX Novavax	-3.75%	-9.42%	+14.66%	-2.84%	+14.23%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AAPG Ascentage Pharma Group International	3.20	Buy	$46.43	199.73% Upside
BBOT BridgeBio Oncology Therapeutics	2.80	Moderate Buy	$22.88	379.56% Upside
BCAX Bicara Therapeutics	2.80	Moderate Buy	$32.64	46.33% Upside
NVAX Novavax	2.33	Hold	$14.00	51.60% Upside

Current Analyst Ratings Breakdown

Latest BBOT, NVAX, BCAX, and AAPG Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/11/2026	BBOT BridgeBio Oncology Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$25.00 ➝ $23.00
9/10/2026	BCAX Bicara Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/10/2026	BBOT BridgeBio Oncology Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$27.00
9/9/2026	BBOT BridgeBio Oncology Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$24.00 ➝ $22.00
9/9/2026	BBOT BridgeBio Oncology Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$23.00 ➝ $15.00
9/9/2026	BBOT BridgeBio Oncology Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$23.00 ➝ $20.00
9/9/2026	BBOT BridgeBio Oncology Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$25.00
8/21/2026	BCAX Bicara Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/21/2026	AAPG Ascentage Pharma Group International	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$48.00
8/18/2026	BCAX Bicara Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$35.00
8/18/2026	BCAX Bicara Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 9/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AAPG Ascentage Pharma Group International	$82.10M	17.62	N/A	N/A	$2.04 per share	7.59
BBOT BridgeBio Oncology Therapeutics	N/A	N/A	N/A	N/A	$5.14 per share	N/A
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	$7.33 per share	N/A
NVAX Novavax	$1.12B	1.36	$3.38 per share	2.73	($0.79) per share	-11.69

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AAPG Ascentage Pharma Group International	-$177.71M	N/A	N/A	774.50	N/A	N/A	N/A	N/A	N/A
BBOT BridgeBio Oncology Therapeutics	-$134.04M	-$2.76	N/A	N/A	N/A	N/A	-46.90%	-42.17%	N/A
BCAX Bicara Therapeutics	-$137.95M	-$3.10	N/A	N/A	N/A	N/A	-41.49%	-38.59%	11/9/2026 (Estimated)
NVAX Novavax	$440.30M	-$1.52	N/A	N/A	N/A	-59.87%	-14.82%	-13.35%	11/5/2026 (Estimated)

Latest BBOT, NVAX, BCAX, and AAPG Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/19/2026	H1 2026	AAPG Ascentage Pharma Group International	N/A	-$0.65	N/A	-$0.6450	N/A	$22.24 million
8/11/2026	Q2 2026	BBOT BridgeBio Oncology Therapeutics	N/A	-$705.20	N/A	-$705.20	N/A	N/A
8/11/2026	Q2 2026	BCAX Bicara Therapeutics	-$0.8198	-$0.82	-$0.0002	-$0.82	N/A	N/A
8/6/2026	Q2 2026	NVAX Novavax	-$0.3798	-$0.32	+$0.0598	-$0.32	$52.51 million	$56.70 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AAPG Ascentage Pharma Group International	N/A	N/A	N/A	N/A	N/A
BBOT BridgeBio Oncology Therapeutics	N/A	N/A	N/A	N/A	N/A
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	N/A
NVAX Novavax	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AAPG Ascentage Pharma Group International	1.09	1.22	1.18
BBOT BridgeBio Oncology Therapeutics	N/A	4.69	4.69
BCAX Bicara Therapeutics	N/A	11.59	11.59
NVAX Novavax	N/A	2.33	2.30

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AAPG Ascentage Pharma Group International	N/A
BBOT BridgeBio Oncology Therapeutics	54.89%
BCAX Bicara Therapeutics	N/A
NVAX Novavax	53.04%

Insider Ownership

Company	Insider Ownership
AAPG Ascentage Pharma Group International	N/A
BBOT BridgeBio Oncology Therapeutics	24.40%
BCAX Bicara Therapeutics	13.80%
NVAX Novavax	1.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AAPG Ascentage Pharma Group International	767	93.40 million	N/A	N/A
BBOT BridgeBio Oncology Therapeutics	88	80.17 million	60.61 million	N/A
BCAX Bicara Therapeutics	103	66.17 million	57.04 million	N/A
NVAX Novavax	749	164.95 million	162.31 million	Optionable

BBOT, NVAX, BCAX, and AAPG Headlines

Recent News About These Companies

Do Novavax’s (NVAX) New Partnerships Offset Policy Risks From The Protecting Approved Care Act?

September 16 at 4:30 AM | finance.yahoo.com

Novavax (NVAX) Could Be 32% Above Fair Value On Medicare Policy Fears

September 16 at 4:30 AM | finance.yahoo.com

Astrana Health, Clover Health, Alignment Healthcare, and Novavax Stocks Trade Down, What You Need To Know

September 15 at 6:29 PM | theglobeandmail.com

Is Cancer the Turnaround Moderna Has Been Looking for Post-COVID?

September 15 at 1:22 PM | finance.yahoo.com

Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know

September 15 at 1:22 PM | finance.yahoo.com

Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know

September 15 at 10:00 AM | zacks.com

Moderna, 10x Genomics, Oscar Health, and Novavax Shares Are Soaring, What You Need To Know

September 12, 2026 | finance.yahoo.com

Novavax (NASDAQ:NVAX) Rating Increased to Hold at Wall Street Zen

September 12, 2026 | marketbeat.com

Novavax (NVAX) Laps the Stock Market: Here's Why

September 11, 2026 | finance.yahoo.com

Novavax (NVAX) Laps the Stock Market: Here's Why

September 11, 2026 | zacks.com

3 Russell 2000 Stocks We’re Skeptical Of

September 10, 2026 | finance.yahoo.com

Novavax Highlights Sanofi, Pfizer Catalysts in Matrix-M Platform Pivot

September 10, 2026 | marketbeat.com

Novavax, Inc. (NVAX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

September 10, 2026 | seekingalpha.com

Novavax (NASDAQ:NVAX) Trading Down 6.5% - Here's Why

September 10, 2026 | marketbeat.com

3 of Wall Street’s Favorite Stocks with Open Questions

September 10, 2026 | finance.yahoo.com

Novavax, Inc. (NASDAQ:NVAX) Receives Average Rating of "Hold" from Analysts

September 10, 2026 | americanbankingnews.com

Novavax, Inc. (NASDAQ:NVAX) Given Average Rating of "Hold" by Brokerages

September 10, 2026 | marketbeat.com

Novavax Highlights Matrix-M Licensing Push, Oncology Ambitions at Cantor Conference

September 10, 2026 | marketbeat.com

Novavax, Inc. (NVAX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

September 9, 2026 | seekingalpha.com

1 Healthcare Stock with Promising Prospects and 2 Facing Headwinds

September 5, 2026 | finance.yahoo.com

NVAX stock holds near 10 dollars as new institutional money arrives

September 4, 2026 | ad-hoc-news.deA

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBOT, NVAX, BCAX, and AAPG Company Descriptions

Ascentage Pharma Group International NASDAQ:AAPG

$15.49 -0.51 (-3.19%)

As of 02:56 PM Eastern

Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.

BridgeBio Oncology Therapeutics NASDAQ:BBOT

$4.76 -0.12 (-2.46%)

As of 02:57 PM Eastern

We are a blank check company incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. Throughout this prospectus, we will refer to this as our initial business combination. We have not selected any specific business combination target and we have not, nor has anyone on our behalf, engaged in any substantive discussions, directly or indirectly, with any potential business combination target with respect to an initial business combination with us. While we may pursue a business combination target in any business or industry, we intend to focus on healthcare or healthcare related industries, which can benefit from the expertise and capabilities of our management team in order to create long-term shareholder value. Our sponsor is an affiliate of Cormorant, a leading life sciences focused investment firm with over $2 billion in assets under management as of December 31, 2022. Our Chairperson and Chief Executive Officer, Bihua Chen, founded Cormorant and is the managing member of Cormorant. Since its inception in 2013, Cormorant has focused on the healthcare industry and invests, throughout their growth cycle, in companies that discover and develop therapeutic drugs or medical technology. Cormorant is an active life-science investor with investments in over 100 privately held, life science-focused companies over this period. Of these investments, over 50 have completed initial public offerings. Notable successes include Prometheus Biosciences, Inc., Turning Point Therapeutics, Inc., and MyoKardia, Inc., each of which has been acquired for more than $4 billion. Other notable successes include BridgeBio Pharma Inc. and Apellis Pharmaceuticals Inc., each of which is a public company with a market capitalization greater than $1 billion. Our executive offices are located at 200 Clarendon Street, 52nd Floor, Boston, MA.

Bicara Therapeutics NASDAQ:BCAX

$22.25 -0.42 (-1.84%)

As of 02:58 PM Eastern

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Novavax NASDAQ:NVAX

$9.24 +0.01 (+0.05%)

As of 02:58 PM Eastern

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BBOT, NVAX, BCAX, and AAPG Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BBOT, NVAX, BCAX, and AAPG Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BBOT, NVAX, BCAX, and AAPG Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBOT, NVAX, BCAX, and AAPG Company Descriptions

Ascentage Pharma Group International NASDAQ:AAPG

BridgeBio Oncology Therapeutics NASDAQ:BBOT

Bicara Therapeutics NASDAQ:BCAX

Novavax NASDAQ:NVAX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BBOT, NVAX, BCAX, and AAPG Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BBOT, NVAX, BCAX, and AAPG Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BBOT, NVAX, BCAX, and AAPG Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBOT, NVAX, BCAX, and AAPG Company Descriptions

Ascentage Pharma Group International NASDAQ:AAPG

BridgeBio Oncology Therapeutics NASDAQ:BBOT

Bicara Therapeutics NASDAQ:BCAX

Novavax NASDAQ:NVAX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools